| Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia S Degryse, CE De Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, ... Leukemia 32 (3), 788-800, 2018 | 87 | 2018 |
| Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance D Staudt, HC Murray, T McLachlan, F Alvaro, AK Enjeti, NM Verrills, ... International journal of molecular sciences 19 (10), 3198, 2018 | 79 | 2018 |
| Nucleotide excision repair deficiency in melanoma in response to UVA HC Murray, VE Maltby, DW Smith, NA Bowden Experimental hematology & oncology 5, 1-11, 2015 | 35 | 2015 |
| Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia HC Murray, AK Enjeti, RGS Kahl, HM Flanagan, J Sillar, ... Leukemia 35 (6), 1782-1787, 2021 | 34 | 2021 |
| Time‐resolved proteomic profiling of cigarette smoke‐induced experimental chronic obstructive pulmonary disease DA Skerrett‐Byrne, EG Bromfield, HC Murray, MFB Jamaluddin, ... Respirology 26 (10), 960-973, 2021 | 27 | 2021 |
| Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia MD Dun, A Mannan, CJ Rigby, S Butler, HD Toop, D Beck, P Connerty, ... Leukemia 34 (12), 3393-3397, 2020 | 19 | 2020 |
| Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer HC Murray, MD Dun, NM Verrills Expert Opinion on Drug Discovery 12 (5), 431-447, 2017 | 19 | 2017 |
| Elucidation of the protein composition of mouse seminal vesicle fluid SP Smyth, B Nixon, AL Anderson, HC Murray, JH Martin, LA MacDougall, ... Proteomics 22 (9), 2100227, 2022 | 17 | 2022 |
| Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma NA Bowden, KA Ashton, RE Vilain, KA Avery-Kiejda, RJ Davey, ... PLoS One 8 (8), e70424, 2013 | 11 | 2013 |
| Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... Science Signaling 16 (778), eabp9586, 2023 | 10 | 2023 |
| Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia HC Murray, K Miller, JS Brzozowski, RGS Kahl, ND Smith, SJ Humphrey, ... Molecular & Cellular Proteomics 22 (3), 2023 | 6 | 2023 |
| Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... Clinical Proteomics 19 (1), 48, 2022 | 5 | 2022 |
| PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, SG Parackal, D Kiltschewskij, IJ Findlay, ... The Journal of clinical investigation 134 (6), 2024 | 4 | 2024 |
| Pharmaco‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G HC Murray, K Miller, MD Dun, NM Verrills Proteomics 24 (9), 2300309, 2024 | 1 | 2024 |
| Immortalized mouse caput epididymal epithelial (mECap18) cell line recapitulates the in‐vivo environment JE Mulhall, NA Trigg, IR Bernstein, AL Anderson, HC Murray, P Sipilä, ... Proteomics 24 (7), 2300253, 2024 | 1 | 2024 |
| Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection (vol 19, 48, 2022) DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... CLINICAL PROTEOMICS 20 (1), 2023 | 1 | 2023 |
| Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... bioRxiv, 2022.03. 09.483687, 2022 | 1 | 2022 |
| Phosphoproteomic analysis of the adaption of epididymal epithelial cells to corticosterone challenge DA Skerrett‐Byrne, SJ Stanger, NA Trigg, AL Anderson, P Sipilä, ... Andrology, 2024 | | 2024 |
| Proteomic and phosphoproteomic characterisation of primary mouse embryonic fibroblasts Y Chen, S Roselli, N Panicker, JS Brzozowski, DA Skerrett‐Byrne, ... Proteomics 24 (7), 2300267, 2024 | | 2024 |
| Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling DE Staudt, ZP Germon, A Mannan, T McLachlan, HC Murray, RJ Duchatel, ... bioRxiv, 2024.07. 26.605229, 2024 | | 2024 |
Matthew D. DunProfessor of Paediatric Haematology/Oncology Research, NHMRC Investigator, College Health & MedicineVerified email at newcastle.edu.au